These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 2535693

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ.
    Cancer Res; 1988 Jul 01; 48(13):3595-602. PubMed ID: 2897875
    [Abstract] [Full Text] [Related]

  • 3. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ, Wang H, Blair GW.
    Cancer Res; 1986 Jun 01; 46(6):2978-83. PubMed ID: 3698020
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
    Deffie AM, Bosman DJ, Goldenberg GJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):6879-82. PubMed ID: 2555055
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST.
    Mol Pharmacol; 1987 Jul 15; 32(1):17-25. PubMed ID: 3037302
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK.
    Mol Pharmacol; 1990 Oct 15; 38(4):471-80. PubMed ID: 2172765
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS, Danks MK, Schmidt CA, Beck WT.
    Cancer Res; 1989 May 01; 49(9):2422-6. PubMed ID: 2539902
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells.
    Sharma R, Arnold L, Gulliya KS.
    Anticancer Res; 1995 May 01; 15(2):295-304. PubMed ID: 7762997
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K, Kohno K, Takano H, Sato S, Kiue A, Kuwano M.
    Cancer Res; 1990 Sep 15; 50(18):5819-24. PubMed ID: 2168282
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH.
    Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479
    [Abstract] [Full Text] [Related]

  • 18. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T.
    Oncol Res; 1995 Apr 15; 7(5):245-52. PubMed ID: 8534930
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 20. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH.
    Cancer Res; 1994 Jan 01; 54(1):152-8. PubMed ID: 7903202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.